In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) have transformed the treatment of ankylosing spondylitis (AS) and brought new attention to this autoimmune disease. Today, a second wave of biological therapies, the IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz), have been approved for AS; these agents’ success will be shaped by the remaining unmet needs in the treatment of this population. In this report, with quantitative insight into U.S. and European rheumatologists’ assessment of the unmet need in AS, we discuss the commercial opportunities for this enigmatic indication and how emerging therapies may capitalize on these opportunities.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in April 2020.
Key companies: AbbVie, Amgen, Eli Lilly, Pfizer, Janssen, UCB, Novartis.
Key drugs: Humira, Enbrel, Remicade, Cimzia, Cosentyx, Taltz.